Milner-Brown H S, Miller R G
J Neurol Sci. 1982 Dec;57(2-3):357-68. doi: 10.1016/0022-510x(82)90041-7.
Ten patients with myasthenia gravis (MG) were treated with weekly plasma exchange (PE) in combination with prednisone and azathioprine; 4 of the patients were treated with 3-6 PE alone, before instituting prednisone/azathioprine. Four clinico-physiological parameters of neuromuscular function as well as the anti-acetylcholine receptor antibody (anti-AChRAb) titers were measured 1-3 times per week. Evidence of improved neuromuscular function (NMF) was based on: (1) reduced % decrement of the maximum muscle compound potential following 2/s supramaximal nerve stimulation; (2) increased maximum force; (3) increased outstretched arm time, and (4) increased vital capacity. An early improvement in NMF occurred within the first 2 weeks (sometimes as early as 1-2 days), which was quantitatively comparable in patients treated with PE alone and PE plus prednisone/azathioprine. This early improvement reached a plateau, and was subsequently maintained for 3-4 weeks, followed by a later substantial improvement after 8-12 weeks of combined PE plus prednisone/azathioprine.
10例重症肌无力(MG)患者接受了每周一次的血浆置换(PE)治疗,并联合使用泼尼松和硫唑嘌呤;其中4例患者在开始使用泼尼松/硫唑嘌呤之前,单独接受了3 - 6次血浆置换治疗。每周测量1 - 3次神经肌肉功能的4项临床生理参数以及抗乙酰胆碱受体抗体(anti - AChRAb)滴度。神经肌肉功能改善的证据基于:(1)2Hz超强神经刺激后最大肌肉复合电位的递减百分比降低;(2)最大力量增加;(3)伸臂时间增加;(4)肺活量增加。神经肌肉功能在最初2周内(有时早在1 - 2天)出现早期改善,单独接受血浆置换治疗的患者与接受血浆置换联合泼尼松/硫唑嘌呤治疗的患者在改善程度上具有定量可比性。这种早期改善达到平台期,随后维持3 - 4周,之后在血浆置换联合泼尼松/硫唑嘌呤治疗8 - 12周后出现后期显著改善。